DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

24 Drugs in Development

24 Drugs in Development

DIGITAL CONTENT

23 NEWS #PharmaBuzz

media
23 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

24DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1009820-21-6, Cx-4945, 5-((3-chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid, Cx4945, Cx 4945, Cx-4945 (silmitasertib)

Molecular Formula

C₁₉H₁₂ClN₃O₂

Molecular Weight

349.8 g/mol

InChI Key

MUOKSQABCJCOPU-UHFFFAOYSA-N

FDA UNII

C6RWP0N0L2

Silmitasertib is an orally bioavailable small-molecule inhibitor of the enzyme casein kinase II (CK2), with potential antineoplastic, anti-viral and immunomodulatory activities. Upon oral administration, silmitasertib selectively binds to and inhibits the activity of CK2. This may inhibit proliferation of CK2-expressing tumor cells, and may also inhibit the replication of severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). In addition, this may restore normal host cell cytokine regulation, prevent cytokine storm and suppress the hyperactivation of the innate immune system. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. CK2 regulates a diverse array of pro-survival cellular processes including epidermal growth factor receptor (EGFR) signaling, PI3K/AKT/mTOR signaling, hedgehog (Hh) signaling, Hsp90 machinery, hypoxia, and interleukin (IL)-6 expression. CK2 also regulates the activity of XRCC1 and MDC1, two mediator/adaptor proteins that are essential for DNA repair. CK2 is upregulated by SARS-COV-2 and is associated with SARS-COV-2 viral replication and the development of cytokine storm.

1 2D Structure

Silmitasertib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid

2.1.2 InChI

InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25)

2.1.3 InChI Key

MUOKSQABCJCOPU-UHFFFAOYSA-N

2.1.4 Canonical SMILES

C1=CC(=CC(=C1)Cl)NC2=NC3=C(C=CC(=C3)C(=O)O)C4=C2C=CN=C4

2.2 Other Identifiers

2.2.1 UNII

C6RWP0N0L2

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic Acid

2. Cx 4945

3. Cx-4945

4. Cx4945

2.3.2 Depositor-Supplied Synonyms

1. 1009820-21-6

2. Cx-4945

3. 5-((3-chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic Acid

4. Cx4945

5. Cx 4945

6. Cx-4945 (silmitasertib)

7. Silmitasertib [inn]

8. Cx4945 (silmitasertib)

9. 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid

10. 5-[(3-chlorophenyl)amino]-benzo[c]-2,6-naphthyridine-8-carboxylic Acid

11. Cx-4945 Free Acid

12. C6rwp0n0l2

13. Silmitasertib (cx-4945)

14. Chembl1230165

15. 5-((3-chlorophenyl)amino)benzo-[c][2,6]naphthyridine-8-carboxylic Acid

16. 5-[(3-chlorophenyl)amino]benzo[c]2,6-naphthyridine-8-carboxylic Acid

17. 5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic Acid

18. 5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic Acid

19. Unii-c6rwp0n0l2

20. Benzo[c]-2,6-naphthyridine-8-carboxylic Acid, 5-[(3-chlorophenyl)amino]-

21. 5-((3-chlorophenyl)amino)benzo(c)(2,6)naphthyridine-8-carboxylic Acid

22. Benzo(c)-2,6-naphthyridine-8-carboxylic Acid, 5-((3-chlorophenyl)amino)-

23. 3ng

24. 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic Acid

25. Silmitasertib; Cx 4945

26. Cx-4945 (silmitaserib)

27. Cx 4945 (silmitasertib)

28. Cx-4945 - Silmitasertib

29. Schembl629082

30. Silmitasertib [who-dd]

31. Gtpl8126

32. Dtxsid40143602

33. Ex-a070

34. Hms3244m13

35. Hms3244m14

36. Hms3244n13

37. Hms3655f16

38. Hms3746e13

39. Bcp02399

40. Bdbm50335638

41. Mfcd13184796

42. Nsc761193

43. Nsc800885

44. S2248

45. Zinc58638454

46. 5-[(3-chlorophenyl)amino]benzo[c]-2,6-naphthyridine-8-carboxylic Acid

47. Akos005266722

48. Bcp9000560

49. Ccg-264955

50. Cs-0563

51. Db15408

52. Ex-8673

53. Nsc-761193

54. Nsc-800885

55. Sb17201

56. Ncgc00263192-01

57. Ncgc00263192-02

58. Ncgc00263192-09

59. Ac-28426

60. As-16253

61. Hy-50855

62. Db-016103

63. Ft-0723994

64. Sw218157-2

65. A25034

66. J-000296

67. J-516169

68. W-204393

69. Cx-4945,cas:1009820-21-6

70. Q27076934

71. 5-[(3-chlorophenyl)amino]pyrido[4,3-c]quinoline-8-carboxylic Acid

2.4 Create Date

2008-03-17

3 Chemical and Physical Properties

Molecular Formula	C₁₉H₁₂ClN₃O₂
Molecular Weight	349.8 g/mol
XLogP3	4.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	5
Rotatable Bond Count	3
Exact Mass	349.0618043 g/mol
Monoisotopic Mass	349.0618043 g/mol
Topological Polar Surface Area	75.1 Å²
Heavy Atom Count	25
Formal Charge	0
Complexity	491
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1